問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberI3O-MC-JSBF
Completed

2016-05-01 - 2020-12-31

Phase II

Terminated5

ICD-10D01.5

Carcinoma in situ of liver, gallbladder and bile ducts

ICD-10C22.0

Liver cell carcinoma

ICD-10C22.1

Intrahepatic bile duct carcinoma

ICD-10C24

Malignant neoplasm of other and unspecified parts of biliary tract

ICD-10C24.9

Malignant neoplasm of biliary tract, unspecified

ICD-9230.8

Carcinoma in situ of liver and biliary system

  • Trial Applicant

    ELI LILLY AND COMPANY(TAIWAN), INC.

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/04/01

Investigators and Locations

Principal Investigator Li-Tzong Chen Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Audit

None

Principal Investigator Yee Chao Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

3 Terminated

Audit

None

Principal Investigator Li-Yuan Bai Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Tai-Jan Chiu Division of Hematology & Oncology

Co-Principal Investigator

  • Yu-Li Su Division of Hematology & Oncology
  • 饒坤銘 Division of Hematology & Oncology
  • 廖浚凱 Division of Hematology & Oncology
  • 陳彥仰 Division of Hematology & Oncology
  • 陳彥豪 Division of Hematology & Oncology

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Li-Yuan Bai 未分科

Co-Principal Investigator

Audit

CRO

Principal Investigator Jen-Shi Chen Division of Hematology & Oncology
Linkou Chang Gung Medical Foundation

Taiwan National PI

陳仁熙

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

7 Terminated

Audit

CRO

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    20 participants

  • Global

    300 participants